by Naomi Schwaitz (Medical Contributor to www,VeinsVeinsVeins.com)
Researchers have done a meta-analysis of randomized controlled trials to determine the efficacy and safety of rivaroxaban (Xarelto) after total hip arthroplasty (THA) and total knee arthroplasty (TKA).
This study was conductd by Dr Liu and colleagues from the Department of Orthopedics, Sanerlingyi Hospital, Hanzhong, China, Second Department of Orthopaedics, Shaanxi Traditional Chinese Medicine Hospital, Xian, China, and the Department of Osteoarthropathy, The WenDeng Osteopath Hospital, Weihai, China.
The primary efficacy outcome of this meta-analysis was the combination of any deep-vein thrombosis (DVT), non-fatal pulmonary embolism (PE), and death from any cause.
This meta-analysis showed that the overall rate of VTE events, DVT, PE, and death were 1%, 6%, < 1% and < 1%, respectively, for patients receiving treatment with rivaroxaban after THA and TKA surgery.
The pooled analysis of bleeding events showed that the overall rate of major bleeding events, overt bleeding events associated with fall in Hb of > 2 g/DL, clinically overt bleeding events leading to transfusion of > 2 units of blood, clinically overt bleeding events leading to further surgeries, and non-major bleeding events were < 1%, < 1%, < 1%, < 1%, and 3%, respectively.
This is the first systematic review of the literature providing incidence of efficacy and safety outcomes for thromboprophylaxis in THA and TKA patients.
This meta-analysis also showed that rivaroxaban had more superior effect in total hip arthroplasty (THA) patients.
Liu J, Zhao J, Yan Y, Su J. Effectiveness and safety of rivarov=xaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis. Medicine 2019; 98. epubication.